Faron Pharmaceuticals Oy has released a detailed analysis of data from the completed Phase 1 part of the ongoing BEXMAB trial. The Phase 2 of the BEXMAB trial is currently enrolling patients to evaluate the safety and efficacy of investigational immunotherapy bexmarilimab at two dose levels in combination with standard of care in patients with hypomethylating agents (HMAs)-refractory or -relapsed myelodysplastic syndrome (MDS).
The new analysis of data from the Phase 1 part of the trial explores the 100% overall response rate achieved among both the higher-risk frontline and HMA-failed MDS patients treated with a bexmarilimab/azacitidine combination. The analysis also examines previous therapies in the patients' treatment pathways, revealing that patients had been previously treated with azacitidine monotherapy or combinations of up to four therapies that included azacitidine or decitabine + magrolimab, venetoclax, and sabatolimab.
Dr. Markku Jalkanen, Chief Executive Officer of Faron, highlighted the significance of the findings, stating, "This analysis shows the deep and durable responses that can be achieved with bexmarilimab in combination with standard of care, in MDS patients who are refractory to HMA therapy or who have relapsed on HMA therapy or HMA/venetoclax combination therapy."
The updated corporate deck containing these data is available on the Company's website. The BEXMAB study is an open-label Phase 1/2 clinical trial investigating bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system.
Faron Pharmaceuticals Ltd. is a global, clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies. Its lead asset, bexmarilimab, is a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function.